Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T88338
(Former ID: TTDS00217)
|
|||||
| Target Name |
Bacterial 23S ribosomal RNA (Bact 23S rRNA)
|
|||||
| Synonyms |
RrnL; Plastid 23S rRNA
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Bacterial infection [ICD-11: 1A00-1C4Z] | |||||
| 2 | Human immunodeficiency virus disease [ICD-11: 1C60-1C62] | |||||
| 3 | Pneumonia [ICD-11: CA40] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 5 Approved Drugs | + | ||||
| 1 | Lefamulin | Drug Info | Approved | Community-acquired pneumonia | [4] | |
| 2 | Linezolid | Drug Info | Approved | Bacterial infection | [5] | |
| 3 | Macrolides | Drug Info | Approved | Bacterial infection | [2] | |
| 4 | Spiramycin | Drug Info | Approved | Bacterial infection | [6] | |
| 5 | Thiamphenicol | Drug Info | Approved | Bacterial infection | [6] | |
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | Cethromycin | Drug Info | Phase 3 | Bacterial infection | [5] | |
| 2 | EDP-420 | Drug Info | Phase 2 | Bacterial infection | [7] | |
| 3 | Oxazolidinones | Drug Info | Phase 2 | Gram-positive bacterial infection | [8] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Inhibitor | [+] 4 Inhibitor drugs | + | ||||
| 1 | Lefamulin | Drug Info | [4] | |||
| 2 | Cethromycin | Drug Info | [5] | |||
| 3 | EDP-420 | Drug Info | [11] | |||
| 4 | Oxazolidinones | Drug Info | [12] | |||
| Binder | [+] 5 Binder drugs | + | ||||
| 1 | Linezolid | Drug Info | [1] | |||
| 2 | Macrolides | Drug Info | [2] | |||
| 3 | Spiramycin | Drug Info | [9] | |||
| 4 | Micrococcin | Drug Info | [9] | |||
| 5 | Thiostrepton | Drug Info | [9] | |||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | Thiamphenicol | Drug Info | [10] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23. | |||||
| REF 2 | Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. | |||||
| REF 3 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||||
| REF 5 | How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. | |||||
| REF 6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 7 | ClinicalTrials.gov (NCT00270517) Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia. U.S. National Institutes of Health. | |||||
| REF 8 | ClinicalTrials.gov (NCT00646958) Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections. U.S. National Institutes of Health. | |||||
| REF 9 | The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. | |||||
| REF 10 | The fused TrpEG from Streptomyces venezuelae is an anthranilate synthase, not a 2-amino-2-deoxyisochorismate [corrected] (ADIC) synthase. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-9-13. | |||||
| REF 11 | EDP-420, a Bicyclolide (Bridged Bicyclic Macrolide), Is Active against Mycobacterium avium. Antimicrob Agents Chemother. 2007 May; 51(5): 1666-1670. | |||||
| REF 12 | Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.